Unlike your GP, urologist, and oncologist, pathologists are not docs that you choose and you’ll likely never meet them. They are associated with labs and with medical practices. They rarely meet patients or speak to them. In fact, in some areas pathologists are barred from speaking to patients. An interview with Dr. Les Raff, head pathologist at UroPartners LLC in Chicago. Read the article here.
A new study published in the Journal of Clinical Oncology has found that men who have higher-than-normal prostate-specific antigen (PSA) levels in middle age are more likely to have fatal prostate cancer later in life. Read the article here.
In a Swedish study, a bacterial species, Propionibacterium acnes, was found in 60 per cent of the prostate cancer biopsies, as opposed to 26 per cent of the controls. Read the article here.
Preventing Overtreatment of Prostate Cancer: New Model Identifies Ideal Patients for Active Surveillance
A new care model for patients with low-risk prostate cancer may help prevent disease overtreatment. This evidence-based approach uses best practices to select patients to avoid disease overtreatment. Results from a 3-year study recently published in Urology indicate that active surveillance (AS) rates nearly doubled after this model was adopted. Read the article here.
Prostate specific antigen, or PSA, tests correctly predicted whether a man would have lethal prostate cancer later in life more than three-quarters of the time, researchers at Harvard University report in a new study. Read the article here.
A “game changer” study has concluded many prostate cancer patients need half as much radiation treatment as currently given. Ontario hospitals are already starting to change treatment to four weeks from the standard eight because of the study led by Hamilton’s Juravinski and Toronto’s Princess Margaret cancer centres. Read the article here.
Metastatic prostate cancer patients respond better to treatment when they switch to different drugs in the absence of an optimal initial response, according to new research from Weill Cornell Medicine and NewYork-Presbyterian. Read the article here.
Up until now, capturing an image of a prostate cancer has been difficult because prostate tissue and tumor tissue are so similar. Precise, non-invasive surgical treatment has proved difficult as a result. Now UCLA researchers report that prostate cancer patients may soon have a new option to treat their disease: laser heat. Read the article here.
Recent findings published in the Annals of Family Medicine showed that most patients with prostate cancer underestimated their life expectancy without treatment and overestimated their life expectancy with treatment. Read the article here.
Scientists at Lawson Health Research Institute in London are the first in Canada to capture prostate cancer images using a new molecule. Known as a Prostate Specific Membrane Antigen (PSMA) probe, the new molecule is used in Positron Emissions Tomography (PET) scans. The probe targets PSMA, a unique molecule on prostate cancer cells, to provide highly specific images for better diagnosis and management of patient disease. Read the article here.